Research
Hormonal
Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.
Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.
StrongSupportsmedium confidence
It offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.
Why this rating
Based on clinical trials mentioned in the abstract.
Source
Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus
Princy Domnic Dsouza et al. · MGM Journal of Medical Sciences · 2025
DOI 10.4103/mgmj.mgmj_386_24
otherCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →